IDEAYA Biosciences financials
$37.86−0.94%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M | $19.5M | $0.00 |
| Gross profit | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M | $19.5M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M | -$50.3M | -$35.3M | -$44.3M |
| Net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M | -$49.8M | -$34.5M | -$42.0M |
| Net margin | −52.0% | −3921.1% | −483.0% | −115.2% | −178.1% | −176.6% | — |
| Diluted EPS | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.40 | $-3.36 |
| EBITDA | -$156.6M | -$324.6M | -$132.0M | -$60.4M | -$47.2M | -$34.0M | -$43.0M |
| Operating cash flow | -$71.1M | -$247.6M | -$115.2M | -$87.2M | -$55.8M | $55.5M | -$39.3M |
| Free cash flow | -$73.5M | -$251.4M | -$117.6M | -$90.6M | -$58.4M | $55.0M | -$40.7M |
| Diluted shares | 88.5M | 81.7M | 57.5M | 41.4M | 35.3M | 24.7M | 12.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $112.8M | $84.4M | $157.0M | $68.6M | $92.0M | $72.0M |
| Short-term investments | $526.6M | $591.9M | $368.1M | $296.2M | $154.7M | $211.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.11B | $1.12B | $649.3M | $388.0M | $381.3M | $298.3M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M | $100.0M |
| Shareholders' equity | $1.02B | $1.06B | $621.1M | $349.5M | $301.5M | $198.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology